Possible Interactions Between Dietary Antioxidants and Chemotherapy

Publication
Article
OncologyONCOLOGY Vol 13 No 7
Volume 13
Issue 7

The use of alternative therapies in combination with cytotoxic chemotherapy is a potentially important clinical issue. Most patients assume that alternative therapies are harmless since they are “not drugs” and, thus, do not have an established

The use of alternative therapies in combination with cytotoxic chemotherapy is a potentially important clinical issue. Most patients assume that alternative therapies are harmless since they are “not drugs” and, thus, do not have an established track record of toxicities. In fact, these agents are generally unregulated, and their lack of toxicity has generally not been confirmed in any large-scale clinical trials.

Drs. Labriola and Livingston concentrate on the specific issue of antioxidants and their potential to interfere with the DNA-damaging actions of cytotoxic agents. I prefer to look at this problem in more general terms. First of all, it is critical to recognize that antioxidants and related alternative therapies are drugs, regardless of whether or not they are normally present in the human body (and, thus, could potentially be considered nutrients). The toxicity of vitamin A, clearly a nutrient, has been well described. An analogous group of “natural” therapies are the cytokines, some of which (ie, interleukin-2) are viewed by most oncologists as being highly toxic.

Pharmacokinetic and Pharmacodynamic Interactions

In approaching the general issue of drug interactions, one has to consider the potential for both pharmacokinetic and pharmacodynamic interactions. Pharmacokinetic interactions result in an alteration in drug elimination (clearance) and, thus, can result in patient exposure to unexpectedly high or low plasma concentrations. The retinoids have the potential to induce their own metabolism, as well as the metabolism of other agents. On the other hand, the flavonoids have the potential to inhibit the metabolism of chemotherapeutic drugs, particularly if both the flavonoid and the drug are taken orally.

Drs. Labriola and Livingston focus their discussion on the potential pharmacodynamic interactions between antioxidants and DNA-damaging agents. They speculate that antioxidants may inhibit the cellular effects of selected cytotoxic agents, while acknowledging that there are sparse data to guide clinical practice.

Complex Dilemma for the Practitioner

The dilemma for the practicing oncologist may be complex. In my own practice, I emphasize to patients that alternative therapies are drugs and, as such, complicate the administration of highly toxic therapies. I also stress that the administration of any drug, even a “natural” compound, has the potential to increase the side effects of cancer chemotherapy. In my experience, this warning usually results in patients avoiding alternative therapies, especially during the critical perichemotherapy period.

Recent Videos
Elucidating nonresponses to bispecific T-cell engagers may be an important research consideration in the multiple myeloma field.
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.
Related Content